Key result
Serum Lp-PLA2 levels were significantly higher in men with both obstructive sleep apnea and metabolic syndrome (median 775.7 ng/mL) compared to those with metabolic syndrome alone (570.9 ng/mL).
Case-Control (n=99)
No
Absolute Event Rate: 775.7% vs 570.9%
p-value: p=0.046
Lp-PLA2 levels are associated with OSAS severity and may serve as a biomarker for predicting cardiovascular disease risk in men with OSAS and metabolic syndrome.
Lp-PLA2 may predict CVD risk in men with OSAS and metabolic syndrome; leaves open prospective validation before clinical adoption.
CONTEXT: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker for cardiovascular diseases (CVD) risk estimation with high specificity for vascular inflammation. Few studies have investigated Lp-PLA2 levels in patients with metabolic syndrome (MetS) and obstructive sleep apnea syndrome (OSAS). OBJECTIVE: This study aimed to evaluate the role of Lp-PLA2 levels as a marker of vascular inflammation that contributes to cardiometabolic dysfunction in patients with MetS and OSAS. DESIGN: This is a prospective case-control study. SUBJECTS AND METHODS: 83 men were enrolled. Following anthropometric measurements, laboratory analysis and overnight sleep study, patients were divided into three groups: MetS, OSAS with/without MetS. Serum Lp-PLA2 levels were determined by ELISA method. RESULTS: , AHI and CRP were significant predictors of Lp-PLA2. CONCLUSIONS: Lp-PLA2 levels are associated with OSAS severity and might play an important role in predicting CVD in OSAS with/without MetS.
No takes yet. Share an insight, caveat, or question.
Laura Moise (2018) conducted a case-control in Metabolic Syndrome and Obstructive Sleep Apnea (n=99). Obstructive Sleep Apnea with Metabolic Syndrome vs. Metabolic Syndrome alone or Healthy Controls was evaluated on Serum Lp-PLA2 levels (ng/mL) (p=0.046). Serum Lp-PLA2 levels were significantly higher in men with both obstructive sleep apnea and metabolic syndrome (median 775.7 ng/mL) compared to those with metabolic syndrome alone (570.9 ng/mL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: